Is this you? Create Your Porfile
Avatar

Francis Thomas Boyle

AstraZeneca

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Francis Thomas Boyle is active.

Explore More

Publication

Featured researches published by Francis Thomas Boyle.

Archive | 2001

Substituted quinolines as antitumor agents

Francis Thomas Boyle; Keith Hopkinson Gibson; Kevin Michael Foote

Archive | 1995

Anti-cancer compounds containing cyclopentaquinazoline ring

Vassilios Bavetsias; Francis Thomas Boyle; Laurent Francois Andre Hennequin; Jonathan Hugh Marriott

Archive | 2003

N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

David William Tonge; Sian Tomiko Taylor; Francis Thomas Boyle; Andrew Hughes; Donna Johnstone; Marianne Ashford; Nigel Charles Barrass

Archive | 2005

3,4-disubstituted maleimides for use as vascular damaging agents

Jean-Claude Arnould; Craig S. Harris; Francis Thomas Boyle; Keith Hopkinson Gibson

Archive | 2000

Derivatives of quinoline as inhibitors for MEK

Francis Thomas Boyle; Keith Hopkinson Gibson; Jeffrey Philip Poyser; Paul Turner

Archive | 1999

Anti-tumour agents

Francis Thomas Boyle

Archive | 2005

A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-`1,3,4-oxadiazol-2-yl!phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer

Francis Thomas Boyle; John Curwen; Andrew Hughes; Donna AstraZeneca R D Alderley Johnstone

Archive | 1999

Anti-tumuor agents

Francis Thomas Boyle

Archive | 2009

Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer

Marianne Ashford; Nigel Charles Barrass; Francis Thomas Boyle; Andrew Hughes; Donna Johnstone; Sian Tomiko Taylor; David William Tonge

Archive | 2005

Combination of N-(3-Methoxy-5-Methylpyrazin-2-Yl)-2-(4-[1,3,4-Oxadiazol-2-Yl]Phenyl)Pyridine-3-Sulphonamide and an Anti-Mitotic Cytotoxic Agent

John Curwen; Andrew Hughes; Donna Johnstone; Francis Thomas Boyle; Gwen Boyle

Explore More

Collaboration

Dive into the Francis Thomas Boyle's collaboration.

Top Co-Authors
Avatar

Andrew Hughes

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Donna Johnstone

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Keith Hopkinson Gibson

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

David William Tonge

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Marianne Ashford

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Nigel Charles Barrass

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Sian Tomiko Taylor

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Jeffrey Philip Poyser

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

John Curwen

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Paul Turner

AstraZeneca

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge